Fa voura bly low ex tra py ra mi dal side effects (EPS) and tar dive dyski ne sia (TD), as well as a broad range of ef fi cacy, suggest that atypi cal an tipsy chot ics could of fer im por tant thera peu tic ad van tages in treat ing con di tions and age groups, ex tend ing be yond their ini tial regu la tory in di ca tions for psy cho sis (1). To ad dress this bur geon ing in ter est, in March and April 1999 we sent a 12-item ques tionnaire (cov er ing use and per ceived in dica tions for nonpsy chotic con di tions and per ceived draw backs to broader use of atypi cals) to Ameri can Psy chi at ric Asso cia tion mem ber psy chia trists in Iowa and Ohio.
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Of 931 sur veys mailed, 284 were returned (re sponse rate 30.5%). Among the 284 re spon dents, 97% had used risperi done, 93% ol an zap ine, 71% queti apine, and 66% clo zap ine in their clini cal prac tice; an over whelm ing major ity (96%) fa vored atypi cals as firstline treat ments for schizo phre nia. For pa tients with bi po lar dis or der or de pression whose con di tion ne ces si tated use of an tipsy chotic medi ca tions, one-half of the phy si cians (50% for bi po lar, 47% for de pres sion) re ported that at least 50% of this pa tient group in their prac tice were re ceiv ing atypi cal (as op posed to typical) an tipsy chot ics. Ad di tion ally, respon dents con sid ered atypi cals to be of thera peu tic ad van tage and had ac tual clini cal ex pe ri ence of their use in con ditions in clud ing de men tia (80% of respon dents), autism (40%), de velopmen tal de lay or men tal re tar da tion (65%), and per son al ity dis or ders (69%). Cli ni cians re ported us ing these drugs to treat ag gres sion (77%), sui ci dal ity (43%), and sub stance abuse (24%). Reported bar ri ers to ex tended use of atypicals clus tered into 3 broad groups: side ef fects (weight gain, hy per gly ce mia, and se da tion were cited as the ma jor draw backs); cost or lack of ac cess (prescrip tion cost, in eq ui ta ble avail abil ity, and non com pli ance); and ef fi cacy or lim ited for mu la tion (un cer tainty re garding ap pro pri ate dos ing, lack of data on long-term use, and the pres ent lack of intra mus cu lar prepa ra tions).
The term "an tipsy chotic" sug gests these drugs are used solely for the pur pose of re liev ing psy chotic phe nom ena. While the atypi cal an tipsy chot ics re duce the inten sity of psy chotic ex pe ri ences, prelimi nary data and clini cal ex pe ri ence also sug gest a broader role, be yond treating psy cho sis, that en com passes the origi nal con cept of "tran quili za tion" (by way of calm ing ef fects on mood, anxiety, and agi ta tion). In par ticu lar, atypicals are in creas ingly used in con di tions where dis tur bances of af fec tiv ity and agi ta tion pre domi nate (1) (2) (3) . Pre scribing prac tices have ad vanced rap idly and to an ex tent that out strips the cur rent evidence base. There is a need to de ter mine in clini cal tri als the risk-bene fit ra tio for each atypi cal an tipsy chotic in these circum stances and also to com pare their effi cacy with that of ex ist ing thera peu tic op tions for nonpsy chotic con di tions.
